Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
-$4.53 today
- Market cap
- $3.01B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
Volume 2.15M
Average 2.42M
LEGN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Legend Biotech CorporationNASDAQ: LEGN
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA turns positive
Q3 FY2026 EBITDA was $64.3M, compared with -$33.19M a year earlier. Trailing-twelve-month EBITDA was $99.55M.
Context
- EBITDA amounted to 22.6% of revenue in FY2025, up 4.5 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of $220.95M (+195.1%) for the fiscal year ending Dec 2026, a step up from the -105.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $64.3M-7.3% QoQ
- Last fiscal yearDec 2025
- -$232.3M-105.3% YoY
- LTMSep 2026
- $99.55M+154.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +293.7% | +1450.0% | +1156.3 pp |
| 1 year | -105.3% | +195.1% | +300.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (232.3M) USD
- Year-over-year change
- -105.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (232.3M) | -105.3% |
| FY2024 | 2024-12-31 | (113.16M) | +76.3% |
| FY2023 | 2023-12-31 | (477.87M) | -14.7% |
| FY2022 | 2022-12-31 | (416.54M) | -6.2% |
| FY2021 | 2021-12-31 | (392.38M) | — |
EBITDA vs competitors
How LEGN compares with its peers on the latest reported figures
- LEGN's LTM Sep 2026 EBITDA of $99.55M is the highest of the 11 companies compared; the peer median is -$114.7M.
- Its year-over-year change of +154.3% is the highest of 11, against a peer median of -12.1%.
- EBITDA amounts to 7.3% of revenue for LEGN, versus a peer median of 624.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $99.55M | +154.3% | — | 7.3% | |
| LTM Mar 2026 | -$5.48M | +4.6% | — | 23.7% | |
| LTM Mar 2026 | -$40.42M | -143.9% | — | 89.7% | |
| LTM Mar 2026 | -$51.11M | -57.3% | — | 75.1% | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| LTM Mar 2026 | -$111.97M | +23.4% | — | 999.5% | |
| LTM Mar 2026 | -$117.42M | +23.4% | — | 1859.1% | |
| LTM Mar 2026 | -$158.55M | -341.7% | — | 8932.3% | |
| LTM Mar 2026 | -$160.41M | +32.7% | — | — | |
| LTM Mar 2026 | -$230.8M | +3.4% | — | 249.3% | |
| LTM Mar 2026 | -$238.99M | -27.7% | — | 770932.3% | |
| Peer median (excluding LEGN) | -$114.7M | -12.1% | — | 624.4% | |
Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.83M | 117.01M | 285.14M | 627.24M | 1.03B |
| Cost of Revenue | 0 | 65.36M | 144.21M | 234.58M | 408.1M |
| Gross Profit | 68.83M | 51.64M | 140.93M | 392.66M | 620.8M |
| Gross Margin | 100.0% | 44.1% | 49.4% | 62.6% | 60.3% |
| Research & Development | 313.35M | 335.65M | 382.22M | 413.54M | 414.7M |
| Selling, General & Admin | 149.5M | 174.05M | 200.93M | 284.26M | 341.6M |
| Operating Expenses | 461.11M | 507.26M | 580.41M | 695.9M | 757.3M |
| Depreciation & Amortization | 13.92M | 18.39M | 20.45M | 23.36M | 28.9M |
| EBITDA | (392.38M) | (416.54M) | (477.87M) | (113.16M) | (232.3M) |
| EBITDA Margin | -570.1% | -356.0% | -167.6% | -18.0% | -22.6% |
| Operating Income | (392.29M) | (455.62M) | (439.49M) | (303.24M) | (136.5M) |
| Operating Margin | -570.0% | -389.4% | -154.1% | -48.3% | -13.3% |
| Interest Income | 971K | 8.18M | 54.49M | 61.2M | 40.1M |
| Interest Expense | 900K | 10.8M | 21.79M | 21.62M | 21.4M |
| Other Income / Expenses | (14.91M) | 9.9M | (80.63M) | 145.11M | (146.1M) |
| Income Before Tax | (407.2M) | (445.72M) | (520.12M) | (158.13M) | (282.6M) |
| Pre-Tax Margin | -591.6% | -380.9% | -182.4% | -25.2% | -27.5% |
| Income Tax Expense | (3.61M) | 625K | (1.86M) | 18.89M | 14.2M |
| Net Income | (403.58M) | (446.35M) | (518.25M) | (177.03M) | (296.8M) |
| Net Margin | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% |
| EPS (Basic) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| EPS (Diluted) | (2.74) | (2.81) | (2.94) | (0.97) | (1.60) |
| Weighted Avg Shares | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
| Weighted Avg Shares (Diluted) | 140.85M | 159.04M | 176.08M | 182.85M | 184.32M |
Legend Biotech Corporation
NASDAQ:LEGN
Intrinsic Alpha fair value
Locked
Current Price
$16.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.